Skip to Main Content

Print | Bookmark | Email | Font Size: + |

ApoE Genotype: Coding and Claim Submission Guidelines

Apolipoprotein (Apo) E genotype testing was developed to assess the risk of cardiovascular disease. Risk assessment for developing a disease or condition in the absence of signs and symptoms of an illness or injury is not defined as a Medicare benefit. CGS has determined that there is insufficient evidence to support the required clinical utility for ApoE genotype testing as a Medicare benefit category. Accordingly, ApoE Genotype tests are statutorily excluded tests.

The following ApoE tests have been identified as non-covered:

Test
ADmark ApoE Genotype Analysis
ApoE
ApoE Genotyping
Apolipoprotein E (APOE) 2 Mutations, Cardiovascular Risk
Apolipoprotein E Genotyping, Blood
ApoE Genotyping
Apolipoprotein E Genotype Analysis
Apolipoprotein E Genotyping
Apolipoprotein E Genotyping

Health care providers are not required to submit claims to Medicare for statutorily non-covered services; however, you may choose to submit claims (e.g., at the patient's request). Claims for ApoE must include:

  • Appropriate CPT code for the test
  • HCPCS modifier GY (statutorily non-covered service)
  • The appropriate ICD-9-CM code(s)
  • The name of the test:
    • Electronic claims: Loop 2400, NTE02, or SV101-7 field
    • Paper claims: Block 19

Reference:

spacer

26 Century Blvd Ste ST610, Nashville, TN 37214-3685 © CGS Administrators, LLC. All Rights Reserved